<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9502153</article-id>
    <article-id pub-id-type="pmid">33978747</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btab366</article-id>
    <article-id pub-id-type="publisher-id">btab366</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Notes</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DetectIS: a pipeline to rapidly detect exogenous DNA integration sites using DNA or RNA paired-end sequencing data</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6308-7540</contrib-id>
        <name>
          <surname>Grassi</surname>
          <given-names>Luigi</given-names>
        </name>
        <xref rid="btab366-cor1" ref-type="corresp"/>
        <aff><institution>Biopharmaceutical Development, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, Cambridge, CB21 6GH, <country country="GB">UK</country></aff>
        <!--luigi.grassi@astrazeneca.com-->
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8695-7537</contrib-id>
        <name>
          <surname>Harris</surname>
          <given-names>Claire</given-names>
        </name>
        <aff><institution>Biopharmaceutical Development, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, Cambridge, CB21 6GH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Jie</given-names>
        </name>
        <aff><institution>Biopharmaceutical Development, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, Gaithersburg, MD 20878, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4992-1268</contrib-id>
        <name>
          <surname>Hardman</surname>
          <given-names>Colin</given-names>
        </name>
        <aff><institution>Data Science &amp; Artificial Intelligence, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, Cambridge, CB21 6GH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hatton</surname>
          <given-names>Diane</given-names>
        </name>
        <aff><institution>Biopharmaceutical Development, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, Cambridge, CB21 6GH, <country country="GB">UK</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Gorodkin</surname>
          <given-names>Jan</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btab366-cor1">To whom correspondence should be addressed. <email>luigi.grassi@astrazeneca.com</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>15</day>
      <month>11</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-05-12">
      <day>12</day>
      <month>5</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>5</month>
      <year>2021</year>
    </pub-date>
    <volume>37</volume>
    <issue>22</issue>
    <fpage>4230</fpage>
    <lpage>4232</lpage>
    <history>
      <date date-type="received">
        <day>16</day>
        <month>10</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>07</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="editorial-decision">
        <day>10</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>11</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="corrected-typeset">
        <day>02</day>
        <month>6</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btab366.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Recombinant DNA technology is widely used for different applications in biology, medicine and bio-technology. Viral transduction and plasmid transfection are among the most frequently used techniques to generate recombinant cell lines. Many of these methods result in the random integration of the plasmid into the host genome. Rapid identification of the integration sites is highly desirable in order to characterize these engineered cell lines.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We developed detectIS: a pipeline specifically designed to identify genomic integration sites of exogenous DNA, either a plasmid containing one or more transgenes or a virus. The pipeline is based on a Nextflow workflow combined with a Singularity image containing all the necessary software, ensuring high reproducibility and scalability of the analysis. We tested it on simulated datasets and RNA-seq data from a human sample infected with Hepatitis B virus. Comparisons with other state of the art tools show that our method can identify the integration site in different recombinant cell lines, with accurate results, lower computational demand and shorter execution times.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>The Nextflow workflow, the Singularity image and a test dataset are available at <ext-link xlink:href="https://github.com/AstraZeneca/detectIS" ext-link-type="uri">https://github.com/AstraZeneca/detectIS</ext-link>.</p>
      </sec>
      <sec id="s5">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Recombinant DNA technology can be used to generate transgenic animals, plants and cell lines, widely used for different applications in biology, medicine and biotechnology (<xref rid="btab366-B5" ref-type="bibr">Ghaderi <italic toggle="yes">et al.</italic>, 2012</xref>; <xref rid="btab366-B7" ref-type="bibr">Khan <italic toggle="yes">et al.</italic>, 2016</xref>). Therapeutic proteins with complex post-translational modifications are normally expressed in mammalian cell lines (<xref rid="btab366-B23" ref-type="bibr">Walsh, 2018</xref>; <xref rid="btab366-B24" ref-type="bibr">Zhu and Hatton, 2018</xref>). Viral transduction and plasmid transfection are methods largely used to establish recombinant cell lines (<xref rid="btab366-B8" ref-type="bibr">Kim and Eberwine, 2010</xref>; <xref rid="btab366-B12" ref-type="bibr">Lee <italic toggle="yes">et al</italic>., 2018</xref>) and typically result in random integration of the transgene construct into the host genome. The identification of the transgene integration site (IS) is important for the characterization of stable recombinant cell lines and, can reveal regulatory features relevant for transgene expression. It can also detect aberrant transgene–host fusion proteins, potentially caused by the plasmid integrating in the proximity of protein-coding genes. Understanding ISs can identify integration ‘hot spots’, i.e. genomic sites conferring high expression of the transgene and data from multiple experiments can be used for the design of targeted ISs. Moreover, as the transgene ISs are unique for an individual transfection event, the IS information can be used to design PCR experiments to assess the clonality of a cell line (<xref rid="btab366-B18" ref-type="bibr">Sommeregger et al., 2013</xref>). Inverse PCR (<xref rid="btab366-B15" ref-type="bibr">Liang et al., 2008</xref>; <xref rid="btab366-B21" ref-type="bibr">Uemura et al., 2014</xref>), splinkerette-PCR (<xref rid="btab366-B22" ref-type="bibr">Uren et al., 2009</xref>) and targeted locus amplification (<xref rid="btab366-B3" ref-type="bibr">de Vree <italic toggle="yes">et al.</italic>, 2014</xref>) are techniques specifically designed to localize ISs in host genomes. High-throughput sequencing (HTS) experiments have been successfully used to localize a similar biological event: the viral ISs in host genomes (<xref rid="btab366-B2" ref-type="bibr">Chen <italic toggle="yes">et al.</italic>, 2019</xref>). Moreover, several studies have proved the usefulness of HTS in localizing plasmid ISs in stable cell lines (<xref rid="btab366-B1" ref-type="bibr">Brett <italic toggle="yes">et al.</italic>, 2011</xref>; <xref rid="btab366-B10" ref-type="bibr">Lambirth et al., 2015</xref>; <xref rid="btab366-B19" ref-type="bibr">Srivastava et al., 2014</xref>). Although pipelines have been developed for detecting viral integration sites, some of them are specifically designed for the human genome reference sequence. Moreover, all the tools require the preparation of indexes specific for each host and exogenous DNA element.</p>
    <p>We present detectIS, a pipeline to detect the ISs in paired end (PE) HTS experiments (either DNA or RNA sequencing data). It can be directly used with different host and exogenous DNA references, without the need of creating a specific index. Consequently, it is suitable for different applications, for example detecting ISs of plasmids in stable cell lines, either clones or pools, as well as locating viruses integrated in any host genome. The speed of execution makes the detectIS pipeline well-suited for quickly screening HTS data from panels of different cell lines generated during the cell line development process for therapeutic protein manufacture, enabling the detection of cell lines with undesirable transgene fusion sequences.</p>
  </sec>
  <sec>
    <title>2 Materials and methods</title>
    <p>DetectIS (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>) consists of three main steps. PE reads are aligned, in single-end mode onto the exogenous sequence reference (i.e. transgene, plasmid or viral sequences). Reads with any overlap with the exogenous reference sequence are subsequently aligned, in single-end mode, to the host genome reference. The alignment is made by using the Minimap2 program (<xref rid="btab366-B13" ref-type="bibr">Li, 2018</xref>). Finally, a <italic toggle="yes">Perl</italic> script integrates the four alignment results looking for potential ISs. ISs can be identified by split reads—read pairs in which at least one read has a part mapping to the host genome and the remaining part mapping to the plasmid/transgene, and chimeric reads, read pairs in which one of the two reads is mapped to the host genome and the other one to the plasmid/transgene. The pseudocode of the subroutines used by the <italic toggle="yes">Perl</italic> script is reported in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figures S2–S9</xref>. Final results are provided as a txt file detailing all the potential ISs and the number of supporting split and chimeric read pairs. The same information is also reported in a markdown file that can be converted to a pdf and/or html file. All the steps of the detectIS pipeline are embedded in a Nextflow (<xref rid="btab366-B4" ref-type="bibr">Di Tommaso <italic toggle="yes">et al.</italic>, 2017</xref>) workflow that, together with the Singularity (<xref rid="btab366-B9" ref-type="bibr">Kurtzer <italic toggle="yes">et al.</italic>, 2017</xref>) container ensures reproducibility and scalability from a single PC/workstation to high-performance computational (HPC) environments.</p>
  </sec>
  <sec>
    <title>3 Usage</title>
    <p>In order to use the workflow, the user has to create a configuration file specifying the reference host genome and exogenous sequence references, the directory containing the raw data and the output directory. The analysis can be executed locally or in an HPC environment, in the latter scenario the user also has to specify the cluster executor. A configuration file is provided to analyze a test dataset and can be used as a template for other analyses.</p>
    <p>The recipe of the Singularity image with all the necessary software is also supplied. A bash script is also given to analyze a test dataset without Nextflow and can be used as a template for analysis in local environments.</p>
    <sec>
      <title>3.1 Comparison with existing tools for structural variant identification</title>
      <p>In order to test the functionality of detectIS and the accuracy of its results, we simulated random integrations of a plasmid in a Chinese hamster ovary (CHO) scaffold, exploring different modalities of transgene size, depth of sequencing coverage and read length. We compared the results of detectIS with the ones derived by other tools for viral detection, that are able to use host references different from human. SeekSV (<xref rid="btab366-B14" ref-type="bibr">Liang et al., 2017</xref>) is a program designed to identify ISs and other structural variants in RNA-seq and DNA-seq experiments and was one of the best performing tools for identifying viral integrations in a recent study (<xref rid="btab366-B2" ref-type="bibr">Chen <italic toggle="yes">et al.</italic>, 2019</xref>). BatVI (<xref rid="btab366-B20" ref-type="bibr">Tennakoon and Sung, 2017</xref>) is a sensitive and fast tool used for the detection of viral integrations that, similarly to detectIS, uses a subtractive strategy where raw reads are aligned to the viral reference genomes in the first instance, and the partially mapped reads are then aligned to the host reference genome to detect viral integrations. SurVirus (<xref rid="btab366-B17" ref-type="bibr">Rajaby et al., 2021</xref>) is a recently published repeat-aware virus integration caller. The detectIS results are among the ones with highest precision and sensitivity in most of the simulated experiments with sequenced read of lengths 250 and 150 bases (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S10A–F, S11–AF</xref>, Supplementary Tables S1–S3). Minimap2 works with read length of 100 bases or higher (<xref rid="btab366-B13" ref-type="bibr">Li, 2018</xref>) and, for this reason, 100 bases is the lowest read length compatible with detectIS. In this simulated scenario, the tool is less precise and sensitive than SurVirus and SeekSV for sequence coverages of 5× and 10×, but performs similarly at higher coverage (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S10–GI, S11G–I</xref>, Tables <xref rid="sup1" ref-type="supplementary-material">Supplementary S1–S3</xref>). The execution times of the analyses are similar for detectIS, SurVirus and BatVI and higher for SeekSV in all the simulated experiments (<xref rid="sup1" ref-type="supplementary-material">Supplementary </xref><xref rid="sup1" ref-type="supplementary-material">Fig. S12</xref>). DetectIS has the lowest computational demands with the lowest CPU times in all the simulated experiments (<xref rid="sup1" ref-type="supplementary-material">Supplementary </xref><xref rid="sup1" ref-type="supplementary-material">Fig. S13</xref>). It is also notable that detectIS can be executed without the reference index generation, a time consuming step required by all the other tools (<xref rid="sup1" ref-type="supplementary-material">Supplementary </xref><xref rid="sup1" ref-type="supplementary-material">Fig. S14</xref>). The integration sites detected by all the used tools have an average discrepancy of a few nucleotides in respect to the original sites (<xref rid="sup1" ref-type="supplementary-material">Supplementary </xref><xref rid="sup1" ref-type="supplementary-material">Fig. S15</xref>). In the simulated integrations, plasmid and host had the same orientation 5′→3′ and this feature was captured by all the tools.</p>
      <p>We extended the comparison to publicly available RNA-seq experiments of four hepatitis B virus (HBV) positive hepatocellular carcinoma cell lines with verified chimeric viral-human transcripts (<xref rid="btab366-B11" ref-type="bibr">Lau et al., 2014</xref>). In this analysis, SurVirus terminated with a segmentation fault error in all the four analyzed experiments and produced an empty final result file in three of them. Analogously, BatVI produced a final result file for only one of the four analyzed experiments, for this reason, we could compare only the results generated by detectIS and seekSV. We defined true positives as ISs that supported the chimeric viral-human transcripts verified in the study of <xref rid="btab366-B11" ref-type="bibr">Lau <italic toggle="yes">et al.</italic> (2014)</xref>, with a tolerance of 50 nucleotides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). The two tools gave similar results in term of precision, sensitivity (<xref rid="sup1" ref-type="supplementary-material">Supplementary </xref><xref rid="sup1" ref-type="supplementary-material">Fig. S16A</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>) and difference from the real data (<xref rid="sup1" ref-type="supplementary-material">Fig. S16B</xref>) with a significantly shorter running time for detectIS (<xref rid="sup1" ref-type="supplementary-material">Supplementary </xref><xref rid="sup1" ref-type="supplementary-material">Fig. S16C</xref> and <xref rid="sup1" ref-type="supplementary-material">D</xref>). This difference in running times can be justified by the fact that the two pipelines are based on different programs and strategies, with seekSV looking for all potential structural variants while detectIS uses a subtractive strategy and is designed to specifically identify variants affecting the exogenous DNA (plasmid/virus). The results presented in this study demonstrate that detectIS is able to identify integration sites in HTS experiments, in a short time without high demands on computational resources. The benchmark analysis indicates that a longer read length improves detectIS precision and sensitivity in experiments made at a lower coverage. The usage of the Minimap2 program for the alignment gives the possibility of running the analysis without any index preparation step and makes the pipeline unique among all the existing programs for viral integration. Due to its versatility, detectIS can be executed to identify viral integration sites in transcriptome or genome sequencing experiments and identify the ISs of plasmids inserted into stable cell lines from HTS experiments routinely made to exclude the presence of variants in transgenic transcripts during clone selection (<xref rid="btab366-B6" ref-type="bibr">Harris <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btab366-B16" ref-type="bibr">Lin et al., 2019</xref>).</p>
      <p><italic toggle="yes">Financial Support</italic>: none declared.</p>
      <p><italic toggle="yes">Conflict of Interest</italic>: none declared.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btab366_Supplementary_Data</label>
      <media xlink:href="btab366_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btab366-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brett</surname><given-names>B.T.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2011</year>) <article-title>Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors</article-title>. <source>PLoS One</source>, <volume>6</volume>, <fpage>e24668</fpage>.<pub-id pub-id-type="pmid">21931803</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>X.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Comprehensive comparative analysis of methods and software for identifying viral integrations</article-title>. <source>Brief. Bioinf</source>., <volume>20</volume>, <fpage>2088</fpage>–<lpage>2097</lpage>.</mixed-citation>
    </ref>
    <ref id="btab366-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Vree</surname><given-names>P.J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping</article-title>. <source>Nat. Biotechnol</source>., <volume>32</volume>, <fpage>1019</fpage>–<lpage>1025</lpage>.<pub-id pub-id-type="pmid">25129690</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Tommaso</surname><given-names>P.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Nextflow enables reproducible computational workflows</article-title>. <source>Nat. Biotechnol</source>., <volume>35</volume>, <fpage>316</fpage>–<lpage>319</lpage>.<pub-id pub-id-type="pmid">28398311</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghaderi</surname><given-names>D.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2012</year>) <article-title>Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation</article-title>. <source>Biotechnol. Genet. Eng. Rev</source>., <volume>28</volume>, <fpage>147</fpage>–<lpage>175</lpage>.<pub-id pub-id-type="pmid">22616486</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname><given-names>C.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis</article-title>. <source>MAbs</source>, <volume>11</volume>, <fpage>1452</fpage>–<lpage>1463</lpage>.<pub-id pub-id-type="pmid">31570042</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2016</year>) <article-title>Role of recombinant DNA technology to improve life</article-title>. <source>Int. J. Genomics</source>, <volume>2016</volume>, <fpage>2405954</fpage>.<pub-id pub-id-type="pmid">28053975</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>T.K.</given-names></string-name>, <string-name><surname>Eberwine</surname><given-names>J.H.</given-names></string-name></person-group> (<year>2010</year>) <article-title>Mammalian cell transfection: the present and the future</article-title>. <source>Anal. Bioanal. Chem</source>., <volume>397</volume>, <fpage>3173</fpage>–<lpage>3178</lpage>.<pub-id pub-id-type="pmid">20549496</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kurtzer</surname><given-names>G.M.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Singularity: scientific containers for mobility of compute</article-title>. <source>PLoS One</source>, <volume>12</volume>, <fpage>e0177459</fpage>.<pub-id pub-id-type="pmid">28494014</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lambirth</surname><given-names>K.C.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2015</year>) <article-title>CONTRAILS: a tool for rapid identification of transgene integration sites in complex, repetitive genomes using low-coverage paired-end sequencing</article-title>. <source>Genome Data</source>, <volume>6</volume>, <fpage>175</fpage>–<lpage>181</lpage>.</mixed-citation>
    </ref>
    <ref id="btab366-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lau</surname><given-names>C.C.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>Viral-human chimeric transcript predisposes risk to liver cancer development and progression</article-title>. <source>Cancer Cell</source>, <volume>25</volume>, <fpage>335</fpage>–<lpage>349</lpage>.<pub-id pub-id-type="pmid">24582836</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>J.S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2018</year>) <article-title>Revealing key determinants of clonal variation in transgene expression in recombinant CHO cells using targeted genome editing</article-title>. <source>ACS Synth. Biol</source>., <volume>7</volume>, <fpage>2867</fpage>–<lpage>2878</lpage>.<pub-id pub-id-type="pmid">30388888</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Minimap2: pairwise alignment for nucleotide sequences</article-title>. <source>Bioinformatics</source>, <volume>34</volume>, <fpage>3094</fpage>–<lpage>3100</lpage>.<pub-id pub-id-type="pmid">29750242</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liang</surname><given-names>Y.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2017</year>) <article-title>Seeksv: an accurate tool for somatic structural variation and virus integration detection</article-title>. <source>Bioinformatics</source>, <volume>33</volume>, <fpage>184</fpage>–<lpage>191</lpage>.<pub-id pub-id-type="pmid">27634948</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liang</surname><given-names>Z.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2008</year>) <article-title>Identifying and genotyping transgene integration loci</article-title>. <source>Transgenic Res</source>., <volume>17</volume>, <fpage>979</fpage>–<lpage>983</lpage>.<pub-id pub-id-type="pmid">18612840</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lin</surname><given-names>T.J.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2019</year>) <article-title>Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics</article-title>. <source>MAbs</source>, <volume>11</volume>, <fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
    </ref>
    <ref id="btab366-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rajaby</surname>,<given-names>R.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>SurVirus: a repeat-aware virus integration caller</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, <volume>49</volume>, <fpage>e33</fpage>  <pub-id pub-id-type="doi">10.1093/nar/gkaa1237</pub-id>PMC: 33444454<pub-id pub-id-type="pmid">33444454</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sommeregger</surname><given-names>W.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2013</year>) <article-title>Transgene copy number comparison in recombinant mammalian cell lines: critical reflection of quantitative real-time PCR evaluation</article-title>. <source>Cytotechnology</source>, <volume>65</volume>, <fpage>811</fpage>–<lpage>818</lpage>.<pub-id pub-id-type="pmid">23807595</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srivastava</surname><given-names>A.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>Discovery of transgene insertion sites by high throughput sequencing of mate pair libraries</article-title>. <source>BMC Genomics</source>, <volume>15</volume>, <fpage>367</fpage>.<pub-id pub-id-type="pmid">24884803</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tennakoon</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sung</surname><given-names>W.K.</given-names></string-name></person-group> (<year>2017</year>) <article-title>BATVI: fast, sensitive and accurate detection of virus integrations</article-title>. <source>BMC Bioinformatics</source>, <volume>18</volume>, <fpage>71</fpage>.<pub-id pub-id-type="pmid">28361674</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uemura</surname><given-names>S.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2014</year>) <article-title>A simple and highly efficient method to identify the integration site of a transgene in the animal genome</article-title>. <source>Neurosci. Res</source>., <volume>80</volume>, <fpage>91</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">24378375</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uren</surname><given-names>A.G.</given-names></string-name></person-group>  <etal>et al</etal> (<year>2009</year>) <article-title>A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites</article-title>. <source>Nat. Protoc</source>., <volume>4</volume>, <fpage>789</fpage>–<lpage>798</lpage>.<pub-id pub-id-type="pmid">19528954</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Walsh</surname><given-names>G.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Biopharmaceutical benchmarks 2018</article-title>. <source>Nat. Biotechnol</source>., <volume>36</volume>, <fpage>1136</fpage>–<lpage>1145</lpage>.<pub-id pub-id-type="pmid">30520869</pub-id></mixed-citation>
    </ref>
    <ref id="btab366-B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hatton</surname><given-names>D.</given-names></string-name></person-group> (<year>2018</year>) <article-title>New mammalian expression systems</article-title>. <source>Adv. Biochem. Eng. Biotechnol</source>., <volume>165</volume>, <fpage>9</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">28585079</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
